Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: To compare two strategies-a hydrocortisone replacement strategy and a prednisone tapering strategy-for their success in glucocorticoid discontinuation in patients with rheumatoid arthritis (RA) with low disease activity (LDA).
Methods: The Strategies for glucocorticoid TApering in Rheumatoid arthritis (STAR) study was a double- blind, double-placebo randomised controlled trial including patients with RA receiving a stable dose of glucocorticoid 5 mg/day for ≥3 months and were in LDA for ≥3 months. Patients were randomly assigned in a 1:1 ratio to either replace prednisone with 20 mg/day of hydrocortisone for 3 months, then reduce to 10 mg/day for 3 months before discontinuation or to taper prednisone by 1 mg/day every month until complete discontinuation, contingent on maintaining LDA. The primary outcome was the percentage of patients achieving glucocorticoid discontinuation at 12 months. Other secondary outcomes were proportion of flares, need for additional glucocorticoid use, disease activity, patient-reported outcomes and the results of adrenocorticotropic hormone (ACTH) stimulation tests.
Results: Of the 102 patients randomised in the trial (mean age 62.4 years, 70.6% females), 53 had hydrocortisone replacement and 49 tapered prednisone. At 12 months, 29 patients (55%) in the hydrocortisone replacement group and 23 patients (47%) in the prednisone tapering group achieved glucocorticoid discontinuation (p=0.4). No difference was observed between groups in the secondary outcomes. No cases of acute adrenal insufficiency were observed; however, 17 patients still had an abnormal ACTH stimulation test at 12 months, with no differences between arms.
Conclusion: A hydrocortisone replacement strategy was not superior to a prednisone tapering strategy for achieving glucocorticoid discontinuation success in patients with RA in LDA.
Trial Registration Number: NCT02997605.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/ard-2024-226620 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mineralocorticoid effects of fludrocortisone and hydrocortisone in primary adrenal insufficiency: EU-AIR patient data.
J Endocrinol Invest
September 2025
Department of Endocrinology and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
Purpose: Patients with primary adrenal insufficiency (PAI) require mineralocorticoid replacement therapy in addition to glucocorticoids. These therapies should be considered in combination because most glucocorticoids also possess mineralocorticoid activity. We aimed to investigate the relationship between fludrocortisone and hydrocortisone-equivalent dosing in patients with PAI.
View Article and Find Full Text PDFMitotane-Induced Endocrine Alterations in Children with Adrenocortical Carcinoma: Clinical Implications from a 20-Year Retrospective Study.
Children (Basel)
August 2025
Department of Pediatrics, University of Turin, 10124 Torino, Italy.
Background/objectives: Mitotane is a key component in the treatment of adrenocortical carcinoma (ACC), but its endocrine side effects in children remain under-characterized.
Methods: We conducted a retrospective analysis of 11 pediatric patients (6 males, 5 females) diagnosed with ACC and followed between 2000 and 2025. Seven received mitotane therapy.
Concomitant Immune Checkpoint Inhibitors Induced Central and Primary Adrenal Insufficiency: A Diagnostic Challenge.
JCEM Case Rep
October 2025
Department of Endocrinology and Diabetology, Hôpitaux Universitaires de Genève, Geneva 1205, Switzerland.
Immune checkpoint inhibitors (ICI) have several endocrine toxicities. Dual sequential pituitary and adrenal toxicities are rare and difficult to diagnose. This case report describes a 63-year-old man with metastatic clear cell renal carcinoma treated with combined nivolumab and ipilimumab.
View Article and Find Full Text PDFManagement Protocols for Sepsis and Septic Shock after Craniotomy: Clinical Outcomes and Survival Analysis.
Asian J Neurosurg
September 2025
Department of Surgery, Phramongkutklao Hospital, Bangkok, Thailand.
Objectives: Central nervous system infections are linked to a substantial rise in perioperative mortality, with postoperative neurosurgical infections being both prevalent and severe. Although the Surviving Sepsis Campaign (SSC) guidelines offer a framework for managing sepsis, their effect on clinical outcomes in neurosurgical patients has yet to be fully explored. The aim of this study was to compare mortality rates and clinical outcomes in neurosurgical patients with sepsis and septic shock treated according to the SSC protocol versus standard care.
View Article and Find Full Text PDFUnveiling Gastrointestinal Involvement in Hypopituitarism: Clinical Features and Treatment Approaches.
Clin Endocrinol (Oxf)
August 2025
Department of Emergency, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
Background: Hypopituitarism, characterized by the deficiency of one or more pituitary hormones, can lead to diverse gastrointestinal (GI) manifestations that are often under-recognized, particularly in elderly patients. These symptoms, ranging from nausea and constipation to severe complications like malabsorption and hepatic dysfunction, can significantly impact patient outcomes if not addressed promptly.
Objective: This review aims to elucidate the GI implications of hypopituitarism, focusing on the clinical features, underlying mechanisms and therapeutic approaches, with an emphasis on hormone replacement therapy (HRT) and its potential benefits and risks.